Evidence map›Paper›PMID 37679976›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2023

Zhenxin Anshen formula ameliorates atopic der-matitis-like skin dysfunction in mice and regulation of transient receptor potential vanilloid 1 and transient receptor potential ankyrin 1 in Neural pathways.

Zhao Yiding, Yan Xiaoning, Jiang Shanshan, Liu Yong, Dong Chun, Chi Huiyan, Mao Chaoyi

Open access · greenAbstract read
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhao YidingDepartment of Dermatology, Shaanxi Provincial Hospital of traditional Chinese Medicine, Xi'an 710003, China.
Yan XiaoningDepartment of Dermatology, Shaanxi Provincial Hospital of traditional Chinese Medicine, Xi'an 710003, China.
Jiang ShanshanDepartment of Dermatology, Shaanxi Provincial Hospital of traditional Chinese Medicine, Xi'an 710003, China.
Liu YongDepartment of Dermatology, Shaanxi Provincial Hospital of traditional Chinese Medicine, Xi'an 710003, China.
Dong ChunDepartment of Dermatology, Shaanxi Provincial Hospital of traditional Chinese Medicine, Xi'an 710003, China.
Chi HuiyanDepartment of Dermatology, Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing 100193, China.
Mao ChaoyiDepartment of Education Management, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Shaanxi Provincial Hospital of Traditional Chinese Medicine · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the efficacy of Zhenxin Anshen formula (, ZXAS) on atopic dermatitis (AD) by transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1) signalling pathway in mice and .

methodsAD-like lesions were induced by 1-chloro-2,4-dinitrobenzene (DNCB) to the shaved dorsal skin of BALB/c mice. BALB/c mice were divided into five groups: normal control, model control, cetirizine, low-, medium-, and high-dose of ZXAS. After ZXAS in-tervention, the skin lesions and blood samples were collected for hematoxylin and eosin-stained and measuring the concentrations of inflammatory cytokines. Immun-oglobulin E (IgE), interleukin (IL)-4, IL-5, IL-13, and thymic stromal lymphopoietin (TSLP) were de-tected by Enzyme-linked immunosorbent assay (ELISA). The spinal cords were collected for measuring the expression of gastrin-releasing peptide receptor (GRPR), TRPV1, and TRPA1 by using immunohistochemistry, western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR) analyses. In addition, 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay, flow cytometry, ELISA, and Western blotting were conducted for analysis of primary dorsal root ganglia (DRG) neurons .

resultsZXAS treatment improved DNCB-induced AD-like lesions through reducing dermatitis score, number of scratching and epidermal thickness, accompanied by the de-creased IgE and Th2 inflammatory cytokines. ZXAS also supressed the mRNA and protein expression of GRPR, TRPV1, and TRPA1 in the spinal cord. The medicated sera of ZXAS decreased capsaicin-induced Ca influx and downregulated the expression of TRPV1, TRPA1, and phospholipase C in DRG neurons.

conclusionsThe therapeutic effect of ZXAS on AD may be related to the regulation of TRPV1 and TRPA1 and inhibition of Ca2+ signals in neurons.

Indexed as

Antineoplastic AgentsDermatitis, AtopicAnimalsAnkyrinsCytokinesDinitrobenzenesDinitrochlorobenzeneImmunoglobulin EMiceNeural PathwaysAnkyrinsAntineoplastic AgentsCytokinesDinitrobenzenesDinitrochlorobenzeneImmunoglobulin Edermatitis, atopicneural pathwayspruritustransient receptor potential ankyrin 1transient receptor potential vanil-loid 1Zhenxin Anshen formula

Identifiers

PMID37679976
PMCPMC10465825
OpenAlexW4386529847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.